Eli Lilly: The Right Long-Term Strategy

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Eli Lilly obesity pill offers superior weight maintenance after injectable GLP-1s

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly’s Weight Loss Superdrug Worked So Well During Trials, Some Quit Over Losing Too Much

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

City takes another step toward bringing $6 billion Eli Lilly facility to Huntsville

The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly's $6 billion facility to the ...

Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
Construction Dive

Lilly to build $6B weight-loss drug factory in Alabama

This is the third of four planned U.S. manufacturing sites the pharmaceutical giant has unveiled this year, set to bring 450 ...
The Economist

The plan to rescue Novo Nordisk

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...